475160-90-8

Basic information

• Product Name: Carbamic acid, [(4-formylphenyl)methyl]-, 9H-fluoren-9-ylmethyl ester
• CAS NO: 475160-90-8
• Molecular Formula: C23H19NO3
• Molecular Weight: 357.409
• Mol File: 475160-90-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [(4-formylphenyl)methyl]-, 9H-fluoren-9-ylmethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [(4-formylphenyl)methyl]-, 9H-fluoren-9-ylmethyl ester(475160-90-8)
• EPA Substance Registry System: Carbamic acid, [(4-formylphenyl)methyl]-, 9H-fluoren-9-ylmethyl ester(475160-90-8)

Safety Data

• Hazardous Substances Data: 475160-90-8(Hazardous Substances Data)

Upstream product

• 475160-89-5 (4-hydroxymethylbenzyl)-carbamic acid 9H-fluoren-9-ylmethyl ester 
• 56-91-7 p-aminomethylbenzoic acid 
• 82911-69-1 N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide 
• 164470-64-8 N-(9-fluorenylmethyloxycarbonyl)-4-(aminomethyl)benzoic acid 

Relevant articles and documents

Selective reduction of carboxylic acids to aldehydes with hydrosilane: Via photoredox catalysis

The direct reduction of carboxylic acids to aldehydes with hydrosilane was achieved through visible light photoredox catalysis. The combination of both single electron transfer and hydrogen atom transfer steps offers a novel and convenient approach to selective reduction of carboxylic acids to aldehydes. The method also features mild conditions, high yields, broad substrate scope, and good functional group tolerance, such as alkyne, ester, ketone, amide and amine groups.

Dioxanes and uses thereof

In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel compounds of general formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1, R2, R3, n, X and Y are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier. The present invention further provides compounds capable of inhibiting histone deacetylatase activity and methods for treating disorders regulated by histone deacetylase activity (e.g., cancer and protozoal infections) comprising administering a therapeutically effective amount of a compound of formula (1) to a subject in need thereof. The present invention additionally provides methods for modulating the glucose-sensitive subset of genes downstream of Ure2p.